Abstract
The involvement of minors in clinical research is inevitable to catch up with the lack of drugs labeled for pediatric use. To encourage the responsible conduct of pediatric clinical trials in the EU, an extensive legal framework has been developed over the past decade in which the practical, ethical, legal, social, and commercial issues in pediatric research are addressed. In this article, the European legal framework surrounding pediatric clinical trials is analyzed from the perspective of the major ethical concerns in pediatric research. The four principles of biomedical ethics will be used as a conceptual framework (1) to map the ethical issues addressed in the European legal framework, (2) to study how these issues are commonly handled in competent adults, (3) to detect workability problems of these paradigmatic approaches in the specific setting of pediatric research, and (4) to illustrate the strong urge to differentiate, specify, or adjust these paradigmatic approaches to guarantee their successful operation in pediatric research. In addition, a concise comparative analysis of the European regulation will be made. To conclude our analysis, we integrate our findings in the existing ethical discussions on issues specific to pediatric clinical research.
Similar content being viewed by others
Notes
A list of countries that signed and/or ratified the convention can be consulted at http://conventions.coe.int/Treaty/Commun/ChercheSig.asp?NT=164&CM=&DF=&CL=ENG.
Similar to the Pediatric Regulation, US Legislation offers (already since 1997) a 6-month extension of marketing exclusivity as a reward for the conduct of pediatric clinical trials. A study of the economic return of the Pediatric Exclusivity Program in the US shows that the economic return of the 6-month exclusivity extension is highly variable with net return-to-cost ratios ranging from −0.84 (i.e., a loss of $11,088,214) to 73.63 (i.e., a profit of $507,899,374) (see Li et al. [23]).
References
Albrecht TL, Franks MM, Ruckdeschel JC (2005) Communication and informed consent. Curr Opin Oncol 17:336–339 doi:10.1097/01.cco.0000166654.23169.a2
Afshar K, Lodha A, Costei A, Vaneyke N (2005) Recruitment in pediatric clinical trials: an ethical perspective. J Urol 174:835–840 doi:10.1097/01.ju.0000169135.17634.bc
Ashcroft R, Goodenough T, Williamson E, Kent J (2003) Children’s consent to research participation: social context and personal experience invalidate fixed cutoff rules. Am J Bioeth 3(4):1–7
Bagley SJ, Reynolds WW, Nelson RM (2007) Is a “wage-payment” model for research participation appropriate for children? Pediatrics 119:46–51 doi:10.1542/peds.2006-1813
Beauchamp TL, Childress JF (2009) Principles of biomedical ethics. Oxford University Press, Oxford
Burke TM, Abramovitch R, Zlotkin S (2005) Children’s understanding of the risks and benefits associated with research. J Med Ethics 31:715–720 doi:10.1136/jme.2003.003228
Conroy S, Newman C, Gudka S (2003) Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children. Ann Oncol 14(1):1–5 doi:10.1093/annonc/mdg031
Council of Europe Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine; Oviedo, 4 April 1997
Council of Europe Additional Protocol to the Convention on Human Rights and Biomedicine, concerning Biomedical Research, Strasbourg, 25 January 2005
Durand-Zaleski IS, Alberti C, Durieux P, Duval X, Gottot S, Ravaud P, Gainotti S, Vincent-Genod C, Moreau D, Amiel P (2008) Informed consent in clinical research in France: assessment and factors associated with therapeutic misconception. J Med Ethics 34:e16 doi:10.1136/jme.2007.023473
Ernest TB, Elder DP, Martini LG, Roberts M, Ford JL (2007) Developing paediatric medicines: identifying the needs and recognizing the challenges. J Pharm Pharmacol 59:1043–1055
European Medicines Agency, Ethical Considerations for Clinical Trials on Medicinal Products conducted with the Paediatric Population. Recommendations of the ad hoc group for the development of implementing guidelines for Directive 2001/20/EC relating to good clinical practice in the conduct of clinical trials on medicinal products for human use. Available at http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-10/ethical_considerations.pdf. Accessed 8 August 2008
European Parliament and the Council. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities, pp L121-34–L121-44
European Parliament and of the Council, Regulation (EC) No. 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No. 726/2004
Gorman RL (2003) The march toward rational therapeutics in children. Pediatr Infect Dis J 22:1119–1123 doi:10.1097/01.inf.0000101846.83256.5a
Grodin MA, Glantz LH (1994) Children as research subjects: science, ethics and law. Oxford University Press, Oxford
Hickey K (2007) Minors’ rights in medical decision making. JONAS Healthc Law Ethics Regul 9(3):100–104 doi:10.1097/01.NHL.0000287968.36429.a9
Hoppu K (1999) Patient recruitment—European perspective. Pediatrics 104(3):623–626
Iltis AS, DeVader S, Matsuo H (2006) Payments to children and adolescents enrolled in research, a pilot study. Pediatrics 118:1546–1552 doi:10.1542/peds.2006-0821
Joffe S, Fernandez CV, Pentz RD, Ungar DR, Mathew NA, Turner CW, Alessandri AJ, Woodman CL, Singer DA, Kodish E (2006) Involving children with cancer in decision-making about research participation. J Pediatr 149:862–868 doi:10.1016/j.jpeds.2006.08.027
Koren G (2003) Healthy children as subjects in pharmaceutical research. Theor Med 24:149–159 doi:10.1023/A:1024694828858
Kuther TL (2003) Medical decision-making and minors: issues of consent and assent. Adolescence 38:343–358
Li JS, Eisenstein EL, Grabowski HG, Reid ED, Mangum B, Schulman KA, Goldsmith JV, Murphy MD, Califf RM, Benjamin DK (2007) Economic return of clinical trials performed under the pediatric exclusivity program. JAMA 297:480–488 doi:10.1001/jama.297.5.480
Lidz CW, Appelbaum PS, Grisso T, Renaud M (2004) Therapeutic misconception and the appreciation of risks in clinical trials. Soc Sci Med 58(9):1689–1697 doi:10.1016/S0277-9536(03)00338-1
Miller VA, Nelson RM (2006) A developmental approach to child assent for nontherapeutic research. J Pediatr 149(1 Suppl):S25–S30 doi:10.1016/j.jpeds.2006.04.047
Pandolfini C, Bonati M (2005) A literature review on off-label drug use in children. Eur J Pediatr 164:552–558 doi:10.1007/s00431-005-1698-8
Rodriguez W, Selen A, Avant D, Chaurasia C, Crescenzi T, Gieser G, Di Giacinto J, Huang SM, Lee P, Mathis L, Murphy D, Murphy S, Roberts R, Sachs HC, Suarez S, Tandon V, Uppoor RS (2008) Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics 121(3):530–539 doi:10.1542/peds.2007-1529
Ross LF (2006) Children in medical research: access versus protection. Oxford University Press, Oxford
Wendler D (2008) Is it possible to protect pediatric research subjects without blocking appropriate research? J Pediatr 152(4):467–470
Acknowledgement
The research for this publication was supported by the EuroCareCF Coordination Action (FP6—contract no. LSHM-CT-2005-18932).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pinxten, W., Dierickx, K. & Nys, H. Ethical principles and legal requirements for pediatric research in the EU: an analysis of the European normative and legal framework surrounding pediatric clinical trials. Eur J Pediatr 168, 1225–1234 (2009). https://doi.org/10.1007/s00431-008-0915-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-008-0915-7